Tempest Therapeutics: Promising Advancements and Strategic Partnerships Justify Buy Rating
Tempest Therapeutics (TPST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
Business Insider10h
Scotiabank Reaffirms Their Buy Rating on Tempest Therapeutics (TPST)
In a report released today, George Farmer from Scotiabank maintained a Buy rating on Tempest Therapeutics (TPST – Research Report), with a price target of $13.00. The company’s shares closed yesterday ...
Tempest Therapeutics: Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Building upon a successful end-of-Phase 2 meeting, received FDA "Study May Proceed" letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced agree ...
Targeted Oncology16h
FDA OKs Study of Amezalpat in Frontline Liver Cancer
The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic ...